% | $
Quotes you view appear here for quick access.

Regenerx Biopharmaceuticals Inc. Message Board

  • snogreen snogreen Jul 20, 2011 2:26 PM Flag

    one thanks to Finkel

    No one outside of this thread knows or cares about TB 4. It is already written off!!!!... because of what Finkel-Boob did on the pressure and venous trials. Maybe I should thank him. I have bought quite a bit lately....and even nibbled on warrants too. The Pressure and Venous areas are good markets...but the DRY EYE market is a $1 billion one...and there is only ONE drug really for that area..RESTASIS - ($700 million sales). And I will say a million times over......RESTASIS got only a 15% response rate. The FDA approval bar is low - as long as we can make statistical significance over placebo.

    ORA Inc is doing the whole trial....and they design it to win. ORA Inc also states in their website that their trials are designed so......that they can be REPLICATED in future trials. Big pharma knows of ORA Inc and believes them. If we pass this phase 2, big pharma will have no choice but to get serious about TB 4. RESTASIS patent expires in less than 2 years also.

    We should have our news within 6 months or so. I only give Finkel ONE kudo......THANK GOD HE CHOSE ORA INC...and got this trial OUT of his hands.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Given the Fink's previous performance, all lousy, this move to ORA could have been forced by ST and/or the BOD.

      If so, let's give credit where credit is due - - -and send the BOD a message, withhold your votes for the Steins
      (annual meeting Aug 3)

    • Thank YOU Ora Inc:

      <<For 30 years, Ora has been at the forefront of ophthalmic clinical research, building an unparalleled track record of success that includes full turnkey clinical services for 32 product approvals within the category. In fact, we have been directly involved in the development of over one-third of the world’s currently marketed ophthalmic pharmaceutical products.

      Ora stands apart from all other research groups in that we have conducted over 1,200 clinical trials and consulting projects within the ophthalmology category. This deep knowledge and expertise has made Ora the preferred ophthalmic drug development partner for many of the top ophthalmic pharmaceutical companies in the world. Our unwavering mission is to apply our core scientific knowledge, regulatory expertise, and clinical excellence to give every drug its best chance to succeed.

      Ora functions as a virtual R&D unit that has helped countless pharmaceutical companies develop new ophthalmic products from molecule to marketplace. Over the past three decades, we have provided turnkey operations for ophthalmic start-ups, mid-sized companies, publicly traded companies, and large multinationals.

      Our reputation has been built upon a solid foundation of scientific rigor and research excellence. Since our founding, we have developed a series of proprietary clinical models that have consistently generated accurate and reliable data to support regulatory approvals, both in the US and around the world.
      We design, execute, and innovate the most efficient ophthalmic clinical development programs in the industry. We dedicate considerable resources towards internal research and development to advance ophthalmic clinical research design, including model innovation and evolution, endpoint development and evaluation, and clinical trial processes and management strategies.>>

0.375-0.007(-1.96%)Oct 9 3:29 PMEDT